Oxycodon Painbreak Pb Pharma

Active Ingredient:: Oxycodone Hydrochloride Ph. Eur.
Origin:: EU

Oxycodon Painbreak Pb Pharma (Oxycodone Hydrochloride Ph. Eur.)

International sale not permitted. Listed for the domestic market and B2B only.

Oxycodone Hydrochloride, the active ingredient in Oxycodon Painbreak Pb Pharma, is an opioid analgesic presented as a 10 mg tablet for oral use. It is employed in the management of moderate to severe pain, typically in adult patients when other analgesics are insufficient.

GNH India supplies Oxycodon Painbreak Pb Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Pb Pharma Gmbh

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Oxycodone Hydrochloride is an opioid analgesic that acts on the central nervous system to relieve pain.

Acute postoperative pain: provides strong analgesia during the recovery period after surgery.
Cancer‑related pain: helps control persistent pain associated with malignant disease.
Severe chronic non‑cancer pain: reduces pain intensity when other treatments have failed.

How It Works

Oxycodone Hydrochloride binds primarily to µ‑opioid receptors in the central nervous system, activating inhibitory G‑protein pathways that decrease neuronal excitability and reduce the transmission of nociceptive signals. This receptor activation also modulates descending pain pathways, producing an overall analgesic effect.

Side Effects

Adverse reactions may range from mild to life‑threatening and should be monitored during therapy.

Common Side Effects

Constipation: reduced gastrointestinal motility.
Nausea and vomiting: upset stomach and emesis.
Drowsiness or sedation: increased sleepiness.
Dizziness: light‑headed sensation.
Dry mouth: reduced salivary flow.
Pruritus: mild itching.

Serious or Rare Side Effects

Respiratory depression: slowed or shallow breathing.
Severe hypotension: marked drop in blood pressure.
Opioid use disorder: dependence or addiction.
Seizures: rare convulsive episodes.
Anaphylaxis: acute allergic reaction with airway compromise.
Adrenal insufficiency: impaired cortisol production.

Precautions & Warnings

Before initiating therapy, clinicians should evaluate patient history and monitor for potential complications.

Assess renal and hepatic function: adjust dosing if impairment is present.
Evaluate for respiratory disorders: avoid use in severe asthma or COPD.
Review concomitant CNS depressants: increased sedation risk.
Counsel on constipation management: use laxatives or stool softeners as needed.
Monitor for signs of dependence: educate patients on proper use.
Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Avoid Interactions

Oxycodone may interact with several drug classes, altering its efficacy or safety profile.

Major Interactions (Avoid)

Benzodiazepines: combined CNS depression can cause profound sedation or respiratory failure.
MAO inhibitors: risk of severe hypertension or serotonin syndrome.
Strong CYP3A4 inhibitors (e.g., ketoconazole): increase oxy‑hydroxy‑oxycodone levels, heightening toxicity.

Moderate Interactions (Monitor Closely)

CYP2D6 inhibitors (e.g., fluoxetine): may reduce conversion to active metabolites, altering analgesia.
CNS depressants (e.g., antihistamines, muscle relaxants): additive sedative effects.
Diuretics: may exacerbate hypotension.
Anticholinergics: increase risk of urinary retention and constipation.

Frequently Asked Questions

Oxycodon Painbreak Pb Pharma contains oxycodone hydrochloride, an opioid analgesic indicated for the management of moderate to severe pain, including postoperative pain, cancer‑related pain, and chronic non‑cancer pain when other analgesics are insufficient.

Oxycodone binds to µ‑opioid receptors in the brain and spinal cord, activating inhibitory pathways that reduce neuronal firing and block the transmission of pain signals, resulting in an overall analgesic effect.

The appropriate dose is determined by the prescribing clinician based on the patient’s pain severity, prior opioid exposure, and individual health factors. Dosage adjustments are made according to clinical response and tolerability.

Opioid analgesics, including oxycodone, are generally contraindicated during pregnancy and lactation because of potential fetal or neonatal respiratory depression and dependence. Use only if the benefits clearly outweigh the risks and under specialist supervision.

Submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Oxycodone offers potent µ‑opioid receptor agonism similar to morphine but with a slightly higher oral bioavailability, making it effective for both acute and chronic pain. Its pharmacokinetic profile differs from drugs such as hydromorphone or fentanyl, influencing dosing frequency and side‑effect patterns.

Store the tablets at temperatures below 25 °C in the original container, protecting them from moisture, heat and direct sunlight. Keep out of reach of children and unauthorized personnel.

The medication is supplied as oral tablets intended for swallowing with water. It should be taken exactly as prescribed, without crushing or chewing, unless a healthcare professional advises an alternative method.

Serious risks include respiratory depression, severe hypotension, opioid dependence or addiction, and rare events such as seizures or anaphylaxis. Patients should be monitored closely for signs of these complications, especially during dose initiation or escalation.

Individuals with known hypersensitivity to oxycodone or any component of the formulation, those with significant respiratory depression, uncontrolled asthma, or severe head injury should avoid this medication. Caution is also advised for patients with a history of substance misuse.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 10 Oct 2026

Disclaimer

International sale not permitted. Listed for the domestic market and B2B only.

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.